Indivior PLC (NASDAQ:INDV) Sees Significant Increase in Short Interest

Indivior PLC (NASDAQ:INDV) saw a large increase in short interest in April. As of April 15th, there was short interest totalling 201,800 shares, an increase of 15.8% from the March 31st total of 174,300 shares. Based on an average daily trading volume, of 129,300 shares, the short-interest ratio is presently 1.6 days. Approximately 0.2% of the shares of the stock are short sold.

Indivior Stock Up 2.0 %

Indivior stock traded up $0.35 during mid-day trading on Monday, hitting $17.93. The company had a trading volume of 165,976 shares, compared to its average volume of 122,442. Indivior has a 12 month low of $14.38 and a 12 month high of $26.50. The stock’s 50 day moving average price is $20.49 and its two-hundred day moving average price is $18.29. The company has a market capitalization of $2.47 billion, a PE ratio of 1,758.00 and a beta of 0.46. The company has a current ratio of 0.92, a quick ratio of 0.74 and a debt-to-equity ratio of 23.50.

Indivior (NASDAQ:INDV) last released its quarterly earnings data on Thursday, February 22nd. The company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.28 by $0.15. Indivior had a net margin of 0.44% and a return on equity of 842.72%. The firm had revenue of $293.00 million during the quarter, compared to analysts’ expectations of $260.00 million. As a group, sell-side analysts anticipate that Indivior will post 2.03 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Craig Hallum began coverage on Indivior in a research note on Wednesday, April 3rd. They issued a “buy” rating and a $37.00 target price for the company.

Institutional Investors Weigh In On Indivior

Several large investors have recently made changes to their positions in INDV. Cannon Global Investment Management LLC bought a new stake in Indivior during the 1st quarter valued at about $563,000. Vanguard Group Inc. increased its position in shares of Indivior by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 5,899,190 shares of the company’s stock valued at $90,081,000 after acquiring an additional 52,836 shares during the period. Royal London Asset Management Ltd. raised its position in Indivior by 5.8% during the 4th quarter. Royal London Asset Management Ltd. now owns 447,828 shares of the company’s stock worth $6,838,000 after buying an additional 24,383 shares during the last quarter. Madison Avenue Partners LP grew its stake in shares of Indivior by 84.9% during the 4th quarter. Madison Avenue Partners LP now owns 72,255 shares of the company’s stock worth $1,103,000 after purchasing an additional 33,168 shares during the period. Finally, Chilton Investment Co. Inc. purchased a new stake in shares of Indivior in the fourth quarter valued at approximately $263,000. 60.33% of the stock is owned by institutional investors.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.